Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease
Overview
Tolerability, efficacy and handling of Berodual® Respimat® 20/50µg/dose solution for inhalation in patients with chronic obstructive airways disease in daily practice
Full Title of Study: “Berodual® Respimat® 20/50µg/Dose Solution for Inhalation in Patients With Chronic Obstructive Airways Disease”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: December 2004
Interventions
- Drug: Berodual® Respimat® solution for inhalation
Arms, Groups and Cohorts
- chronic obstructive airways disease patients
Clinical Trial Outcome Measures
Primary Measures
- Change in overall severity rated on 3-point scale
- Time Frame: up to 4 weeks
- Change in reduction in breathlessness rated on a 4-point scale
- Time Frame: up to 4 weeks
- Change in restriction of activity due to breathlessness rated on a 4-point scale
- Time Frame: up to 4 weeks
- Number of awakening due to nocturnal breathlessness rated on 4-point scale
- Time Frame: up to 4 weeks
- Global assessment of efficacy by the patients rated on 5-point scale
- Time Frame: after 4 weeks
- Global assessment of efficacy by the investigator rated on 5-point scale
- Time Frame: after 4 weeks
- Number of patients with adverse drug reactions
- Time Frame: up to 4 weeks
Participating in This Clinical Trial
Inclusion Criteria
- Men and women presenting with symptoms of chronic obstructive pulmonary disease – Both previously untreated patients and patients treated previously with Berodual® or with other anti-obstructive respiratory tract agents may be included Exclusion Criteria:
- Patients presenting with the general and specific contraindications listed in the Patient Information Leaflet and the Basic Product Information
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Boehringer Ingelheim
- Provider of Information About this Clinical Study
- Sponsor
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.